Psychedelics like Ketamine NOW getting Second Look

NOT INTERESTED? [‘UNSUBSCRIBE’]( <--CLICK Investor Marketing designed for growth Greetings Investors, As late as 1960, psychedelics were fully legal and widely regarded as a promising line of psychological research. But just a few years later, the political and cultural winds made the country go into a full-blown panic over psychedelics. Psychedelics like ketamine are now getting a second look as a way to treat psychiatric problems like depression, anxiety, substance disorders, and PTSD. Ketamine had become one of the biggest breakthroughs in mental health care when a surprising thing happened in 2006.... Researchers at the National Institutes of Health showed that an intravenous dose could relieve severe depression in only a matter of hours! Now take a look at this article from NPR: [( There is a snippet that reads: "For six years now, life has been really good for James. He has a great job as the creative director of an advertising firm in New York City. He enjoys spending time with his wife and kids. And it has all been possible, he says, because for the past six years he has been taking a drug called ketamine." These are the kind of stories that show how much promise ketamine is offering to psychiatry. While this field of medicine has come a long way, there is no dying that there is still so much left to be done. Newly listed NASDAQ company Pasithea Therapeutics Corp. (NASDAQ: KTTA) is dedicated to pioneering new treatments and helping as many people as possible to reclaim their lives and is on a mission to help those suffering from psychiatric conditions. The goal? To provide cutting edge treatments with leading scientific research and data that will give the results people have been waiting for. KTTA is targeting treatment-resistant depression and PTSD using ketamine infusions. In fact, the company intends to operate mental health clinics using board certified anesthesiologists to administer intravenous infusions of ketamine. What makes this company truly sound out is that they want to deliver ketamine infusions in the comfort of a patient’s home! By eliminating the need to leave the house will be a big relief for millions of people suffering from mental health disorders such as depression. The world is in desperate need for a revolution in mental health care. The status quo today is simply unacceptable. Moving away from traditional practices and thinking may be the only way to bring a sea of change to one of the most important areas in the massive healthcare space. Did you know that the World Health Organization (WHO) has even placed ketamine on its list of essential substances that should be available to patients in any health system? Being fresh to the NASDAQ makes KTTA one to pay very close attention to as the world begins to learn about what the company is doing. This small cap company only debuted in September of 2021! It was also in September that the very first active psychedelics ETF in the country had hit the NYSE. Not only the world, but Wall Street too is waking up to the promising benefits of ketamine in medicine. As the biotech space heats up, KTTA is an undiscovered NASDAQ company set to shine as it tackles today's mental health epidemic in a unique way... --------------------------------------------------------------- [Download the Pasithea Therapeutics Investor Report]( [Pasithea Therapeutics logo]( [A woman with a nurse looking at each other and smiling, The nurse is holding a tablet and pointing to it.] Pasithea Therapeutics Corp. (NASDAQ: KTTA), a biotechnology company, engages in research and discovery of treatments for psychiatric and neurological disorders. The company also intends to operate anti-depression clinics and provide business support services using trained pharmacists to administer intravenous infusions of ketamine. Pasithea Therapeutics Corp. was incorporated in 2020 and is based in Miami Beach, Florida. [Download the Investor Report now to learn more about this opportunity.]( [DOWNLOAD THE REPORT]( No longer want to receive these emails? [Unsubscribe](. TradigitalIR 12 E 49th Street, 11th Fl. New York, NY 10017 This Website Is Wholly Owned By Tradigital Marketing Group, Inc. (D/B/A “Tradigital Ir”). Our Reports Are Advertorials And Are For General Information Purposes Only. Never Invest In Any Stock Featured On Our Site Or Emails Unless You Can Afford To Lose Your Entire Investment. The Disclaimer Is To Be Read And Fully Understood Before Using Our Services, Joining Our Email List, As Well As Any Social Networking Platforms We May Use. Please Note Well: Tradigital Ir And Its Employees Are Not Registered Investment Advisors, Broker-Dealers, Or Member(S) Of Any Association For Other Research Providers In Any Jurisdiction Whatsoever. Release Of Liability: Through Use Of This Website, Viewing Or Using You Agree To Hold Tradigital Ir, Its Operators, Owners, And Employees Harmless And To Completely Release Them From Any And All Liability Due To Any And All Loss (Monetary Or Otherwise), Damage (Monetary Or Otherwise), Or Injury (Monetary Or Otherwise) That You May Incur. The Information Contained Herein Is Based On Sources That We Believe To Be Reliable But Is Not Guaranteed By Us As Being Accurate And Does Not Purport To Be A Complete Statement Or Summary Of The Available Data. Tradigital Ir Encourages Readers And Investors To Supplement The Information In These Reports With Independent Research And Other Professional Advice. All Information On Featured Companies Is Provided By The Companies Profiled Or Is Available From Public Sources And Tradigital Ir Makes No Representations, Warranties, Or Guarantees As To The Accuracy Or Completeness Of The Disclosure By The Profiled Companies. None Of The Materials Or Advertisements Herein Constitute Offers Or Solicitations To Purchase Or Sell Securities Of The Companies Profiled Herein And Any Decision To Invest In Any Such Company Or Other Financial Decisions Should Not Be Made Based Upon The Information Provided Herein. Instead, Tradigital Ir Strongly Urges You To Conduct A Complete And Independent Investigation Of The Respective Companies And Consideration Of All Pertinent Risks. Tradigital Ir’s Full Disclosure Is To Be Read And Fully Understood Before Using Tradigital Ir's Website, Or Joining Tradigital Ir's Email Or Text List. From Time To Time, Tradigital Ir Will Disseminate Information About A Company Via Website, Email, Sms, And Other Points Of Media. By Viewing Tradigital Ir's Website And/Or Reading Tradigital Ir's Email Or Text Newsletter You Are Agreeing ----> [(. All Potential Percentage Gains Discussed In Any Communications Are Based On Calculations From The Low To The High Of The Day. We Are Engaged In The Business Of Marketing And Advertising Companies For Monetary Compensation. in Compliance With Section 17(B) Of The Securities Act We Are Disclosing That We have Been compensated A Fee Pursuant To An Agreement Between Tradigital And Pasithea Therapeutics Corp. Tradigital Was Hired For A Period Beginning January 2022 And Ending March 2022 To Publicly Disseminate Information About Pasithea Therapeutics Corp. Via Website, Email, And Sms. We Were Paid Five Hundred Forty-Four Thousand Usd Via Ach. We Own One Hundred Fifty Thousand Restricted Common Shares Of Pasithea Therapeutics Corp., Which Are Eligible For Sale On 03/18/2022. For The Purpose Of This Disclaimer, We Suggest That You Assume We Will Sell All Of Our Shares Once The Restriction Is Lifted On 03/18/2022. Readers Are Advised To Review Sec Periodic Reports: Forms 10-Q, 10k, Form 8-K, Insider Reports, Forms 3, 4, 5 Schedule 13d. Tradigital Ir Is Compliant With The Can-Spam Act Of 2003. Tradigital Ir Does Not Offer Investment Advice Or Analysis, And Tradigital Ir Further Urges You To Consult Your Own Independent Tax, Business, Financial, And Investment Advisors. Investing In Micro-Cap, Small-Cap, And Growth Securities Is Highly Speculative And Carries An Extremely High Degree Of Risk. It Is Possible That An Investors Investment May Be Lost Or Impaired Due To The Speculative Nature Of The Companies Profiled.The Private Securities Litigation Reform Act Of 1995 Provides Investors A Safe Harbor In Regard To Forward-Looking Statements. Any Statements That Express Or Involve Discussions With Respect To Predictions, Expectations, Beliefs, Plans, Projections, Objectives, Goals, Assumptions Or Future Events, Or Performance Are Not Statements Of Historical Fact May Be Forward-Looking Statements. Forward-Looking Statements Are Based On Expectations, Estimates, And Projections At The Time The Statements Are Made That Involve A Number Of Risks And Uncertainties Which Could Cause Actual Results Or Events To Differ Materially From Those Presently Anticipated. Forward-Looking Statements In This Action May Be Identified Through The Use Of Words Such As Projects, Foresee, Expects, Will, Anticipates, Estimates, Believes, Understands, Or That By Statements Indicating Certain Actions & Quotes; May, Could, Or Might Occur. Understand There Is No Guarantee Past Performance Will Be Indicative Of Future results In Preparing This Publication, Tradigital Ir Has Relied Upon Information Supplied By Its Clients, As Well As Its Clients’ Publicly Available Information And Press Releases Which It Believes To Be Reliable; However, Such Reliability Can Not Be Guaranteed. Investors Should Not Rely On The Information Contained On This Website. Rather, Investors Should Use The Information Contained In This Website As A Starting Point For Doing Additional Independent Research On The Featured Companies. The Advertisements In This Website Are Believed To Be Reliable, However, Tradigital Ir And Its Owners, Affiliates, Subsidiaries, Officers, Directors, Representatives, And Agents Disclaim Any Liability As To The Completeness Or Accuracy Of The Information Contained In Any Advertisement And For Any Omissions Of Materials Facts From Such Advertisement. Tradigital Ir Is Not Responsible For Any Claims Made By The Companies Advertised Herein, Nor Is Tradigital Ir Responsible For Any Other Promotional Firm, Its Program, Or Its Structure. tradigital Ir Is Not Affiliated With Any Exchange, Electronic Quotation System, The Securities Exchange Commission, Or Finra. ‌